Clinical evaluation of new global clotting assay for monitoring of LMWH treatment: Pilot study

International Angiology

Volumn 17, Issue 2, 1998, Pages 69-79

  Makris, P E ^a   Pithara, E L ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Heparin, low molecular weight; Thromboembolism drug therapy

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ARTICLE; ATHU TEST; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PILOT STUDY; REPRODUCIBILITY; SCHOOL CHILD; STATISTICAL ANALYSIS; THROMBOEMBOLISM; THROMBOPHILIA;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION TESTS; EVALUATION STUDIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; VENOUS THROMBOSIS;

EID: 0031757220     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hirsh J. Low molecular weight heparin. Thromb Haemost 1993;70(1):204-7.
2. Seitz J, Hirsh J. New anticoagulant strategics. J Lab Clin Med 1993;122:364-73.
3. Hemker HC. The mode of action of heparin in plasma. In: Verstraete M, Vermylen J, Lijnen HR, Arnout J, editors. Thrombosis and Haemostasis. Leuven: Univ Press 1987:17-36.
4. Beguin S, Hemker HC. Mode of action of heparin and related drues. Semin Thromb Hemost 1991;17(Suppl 1):29-34.
5. Hemker HC, Beguin S. Determination of heparin in blood. In: Keber D, editor. Haemostasis and Thrombosis. Med Razgl 1990;29(Suppl 3):95-110.
6. Bergqvist D, Burnark US, Frisell et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective doubleblind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986;73:204-8.
7. Hirah J, Dalen JE, Deykin D, Poller L. Heparin mechanism of action, pharmacokinetics, dosing considerotions, monitorine, efficacy, and safety. Chest 1992;102:337s-51s.
8. Samama MM, Gerotziafas GT. Low molecular weight heparins for prevention of venous thomboembolism in medical patients. In: Bounameaux H, editor. Low molecular weight heparins in prophylaxis and treatment of thromboembolic diseases. 1994:225-40.
9. Leizorovicz A, Hough M, Chapuis F, Samama MM, Bolssel JD. Low molecular weight heparin in prevention of postoperative thrombosis. Br Med J 1992;305:913-20.
10. Jorensen LN, Wille Jorensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993;80:689-704.
11. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Welis PS, Hirsh J. Efficacy and cost of low molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105-12.
12. Leizorovicz A, Simmonneau G, Decousus H. Comparison of low molecular weight heparin and unfractionated heparin in the treatment of DVT: a inetaanalysis. Thromb Haemost 1993;69:647(abstract).
13. Nurmohamed MT, Rosendal FR, Buller HR et al. Low molecular weight heparin in general and orthopedic surgery, a meta-analysis. Lancet 1992;640:152-6.
14. Poller L, Taberner DA, Sandilands DG, Galusco CS. An evaluation of aPTT monitoring of low-dose heparin dosage in hip surgery. Thromb Haemost 1982; 47:50-3.
15. Basu D, Gallus A, Hirah J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:325-7.
16. Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvond J, Livio J. Adjusted versus fixed doses subcutaneous heparin in the prophylaxis of deep vein thrombosis after total hip replacement. N Engl J Med 1983;309:954-8.
17. Tabener DA, Poller L, Thomson J. A randomised study of adjusted dose heparin versus fixed low dose heparin in the prophylaxis of deep vein thrombosis in hip surgery. Br J Surg 1989;76:933-5.
18. Collins R, Serimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988;318:1162-73.
19. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994;72:330-4.
20. Lyon SG, Lasser EC, Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect on antithrombin III concentration. Thromb Haemost 1987;58:884-7.
21. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF et al. Adjusted versus fixed doses of the low molecular weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702.
22. Dignac M, Gabaig AM, Cambus JP, Boneu B. A new chronometric assay to determine plasma anti-factor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins. Nouv Rev Fr Hematol 1994;35(6):545-9.
23. Makris PE, Pithara E, Dimitriadou K, Louizou C. LMW-Heparin's monitoring: New method, ATHU-test. Jn: Balas P, editor Progress in Angiology 1991. Torino. Edizioni Minerva Medica, 1991:255-8.
24. Tsukada T. An international attempt for standardization on terminology and methodology in hemostasis and thrombosis. Thromb Haemost 1994;35: 469-74.
25. Palm M, Mattsson C, Magnus Svahn C, Weber M. Bleeding time in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity. Thromb Haemost 1990; 64:127-32.
26. Bendetowz AV, Kal H, Knebel R et al. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma a study in human volunteers. Thromb Haemost 1994;72(5);705-12.
27. Yang X, Blajchman MA, Craven S, Smith LM, Anvari N, Ofosu FA. Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and H-D-PHE-PROARGCH2CL. Biochem J 1990;272:399-406.
28. Carter Cj, Kelton JC, Hirsh J et al. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982;59:1239-45.
29. Schmitz Huebner U, Bunte H, Freise G et al. Clinical efficacy of low molecular weight heparin in post-operative thrombosis prophylaxis. Klin Wochensc 1984;62:349-53.
30. Thery C, Simonneau G, Meyer G et al. Randomised trial of subcutaneous low molecular weight heparin, CY216, (Fraxiparine) compared with intravenous unfractinated heparin in the curative treatment of submassive pulmonary embolism: a dose ranging study. Circulation 1992;85:1380-9.
31. Samama MM, Bernard P, Bonnardot JP, Combe-Tamzali et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128-31.
32. Bratt G, Tornebohm E, Gmaqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb Haemost 1989;59:813-7.
33. Leizorovicz A, Bara L, Samama MM, Haugh. Factor Xa inhibition: Correlation between the plasma level of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993;23(Suppl 1):89-98.
34. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
35. Leizorovicz AA, Picolet H, Peyreyk JC, Boissel JP and HBPM group. Prevention of perioperative deep vein thrombosis in general surgery, a multicentre double-blind study comparing two doses of logiparin and standard heparin. Br J Surg 1991;78:412-6.
36. Levine MN, Planes A, Hirsh J et al. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-4.
37. Hull R, Raskob GE, Pineo G et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-82.
38. Spiro TE and the Enoxaparin Clinical Trial group. A randomised, trial of Enoxaparin administered postoperative for the prevention of deep vein thrombosis following eletctive hip replacement surgery. Thromb Haemost 1991;65:927(abst).
39. Bara L, Samama M. The need for standardisation of low molecular weight heparin (LMWH). Thromb Haemost 1986;56:418.
40. Thomas DP, Curtis AD, Barrowcliffe TW. A collaborative study designed to establish the 4th International Standard for heparin. Thromb Haemost 1984;52:148-53.
41. Barrowcliffe TW, Curtis AD, Tomlinson TP et al. Standardisation of a low molecular weight heparins: a collaborative study, Thromb Haemost 1985;54:675-9.
42. Barrowcliffe TW, Johnson EA, Thomas DP. Measurement of in vitro anticoagulant activities. In: Low Molecular Weight Heparin. New York: ed., Willey & Sons, 1992:45-63.
43. Walenga JM, Bara L, Samama MM, Fareed J. Amidolytic anti-factor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Semin Thromb Haemost 1985;11:100-7.
44. Koller M, Schoch U, Buchmann F, Largiader F, von Felten, Frick PC. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomised double-blind study versus unfractionated heparin. Thromb Haemost 1986;56: 243-6.
45. Kakkar W, Cohen AT, Edmonson RA et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-65.
46. Wagenvooed RJ, Hendrix HH, Kolde HJ, Hemker HC. Development of a rapid and sensitive chromogenic heparin assay for clinical use. Haemostasis 1993;23:26-37.
47. Hemker HC, Wielders S, Kessels Ho, Beguin S. Continuous registration of thrombin generation in plasma, in use for the determination of the thrombin potential. Thromb Haemost 1994;70:617-24.
48. Bara L, Bloch MF, Zitoun D et al. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation and release of tissue factor pathway inhibitor. Thromb Res 1993;69:343-52.
49. Gerotziafas G, Bara L, Bloch MF, Makris PE, Samoma MM. Treatment with LMWHs inhibits in vitro factor VII activation. Preliminary results. Haemostasis 1994;24:S1-244.